Spero Therapeutics Inc (NAS:SPRO)
$ 1.03 0.0861 (9.12%) Market Cap: 56.15 Mil Enterprise Value: -20.21 Mil PE Ratio: 12.88 PB Ratio: 0.85 GF Score: 39/100

Spero Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript

Sep 26, 2023 / 08:20PM GMT
Release Date Price: $1.21 (+0.83%)
Louise Chen Cantor Fitzgerald;Analyst

Hi, good day. My name is Louise Chen. I'm the large cap pharma, biopharma, and biotech analyst here at Cantor. I would like to introduce you today Sath Shukla, the President and CEO of Spero Therapeutics.

Sath, maybe to start, you could give us your company vision, what Spero is focused on, and how do you think about the company over the next three to five years.

Sath Shukla Spero Therapeutics
Inc. - President & CEO

Okay. Thanks for having me, Louise. The company was founded roughly 10 years ago to then combat the growing threat of antibiotic resistance. Over the past few years, particularly with our acquisition of an asset in NTM, the company now sees itself as a leader in rare and infectious diseases.

We have multiple late-stage assets that we hope will provide differentiated therapies in areas of high unmet patient need and strong economic prospects. That's been the mandate for the company over the past several years. And over the next three to five years, it's continuing execution in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot